OPC-6535

DRUG2 trials

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Co., Ltd.

Conditions

Crohn's DiseaseUlcerative Colitis

Phase 2

A Dose-finding and Confirmatory Trial of OPC-6535 in Patients With Active Crohn's Disease

CompletedNCT00989573

Otsuka Pharmaceutical Co., Ltd.Crohn's Disease

Start: 2009-10-31End: 2012-08-31Updated: 2021-04-06

Phase 3

CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission

CompletedNCT00092508

Otsuka Pharmaceutical Development & Commercialization, Inc.Ulcerative Colitis

Start: 2004-05-31End: 2007-05-31Target: 1725Updated: 2007-06-21